Search Results

The Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit is intended as a qualitative test for the detection of IgG and IgM antibodies to Borrelia burgdorferi sensu stricto in human serum from symptomatic patients or people suspected of infection. When used as the first-tier screening test, positive and equivocal results must be confirmed through additional testing by one of the following methods:

• Standard two-tier test methodology (STTT) using an IgG and/or IgM blot testing following current interpretation guidelines, OR

• Modified two-tier test methodology (MTTT) using the Gold Standard Diagnostics Borrelia burgdorferi VlsE-OspC IgG/ IgM ELISA Test.

The assay can also be used as a second-tier confirmation test using the MTTT methodology when used with the Gold Standard Diagnostics Borrelia burgdorferi VlsE-OspC IgG/IgM ELISA Test as the first-tier screening test.

Positive test results by either the STTT or MTTT methodology are supportive evidence for the presence of antibodies and exposure to Borrelia burgdorferi, the cause of Lyme disease. A diagnosis of Lyme disease should be made based on the presence of Borrelia burgdorferi antibodies, history, symptoms, and other laboratory findings.

The kit includes 12 x 8 well Antigen Coated strips, Conjugate, Substrate, Stop Solution, Wash Buffer, Diluent, Negative Control, Positive Control, and Cutoff Control. The controls are provided to determine if the assay is functioning properly and to determine the antibody level. The reagents are sufficient for 96 determinations.

During the test procedure, antibodies to B. burgdorferi (sensu stricto) if present in the human serum sample will bind to the antigens coated onto the wells forming antigen-antibody complexes. Excess antibodies are removed by washing. A conjugate of goat anti-human IgG/IgM antibodies conjugated with horseradish peroxidase are then added, which binds to the antigen-antibody complexes. Excess conjugate is removed by washing. This is followed by the addition of a chromogenic substrate, tetramethylbenzidine (TMB). If specific antibodies to the antigen are present in the patients' serum, a blue color will develop. The enzymatic reaction is then stopped with a stopping solution causing the contents of the well to turn yellow. The wells are read photometrically with a microplate reader at 450nm.

The antigens used in the Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test kit is a combination of B. burgdorferi sensu stricto strain B31 lysate, B. burgdorferi sensu stricto strain 2591 lysate, and a recombinant VlsE from B. burgdorferi sensu stricto strain B31. The lysates use spirochetes growing in BSK-H complete medium until mid-exponential phase. The recombinant VlsE protein is produced in E. coli SURE2 cells and purified by affinity chromatography. The purity of each antigen is assayed by SDS-PAGE followed by Coomassie staining and/or Western blotting.

The provided document describes the Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit and its performance in various studies. Here's a breakdown of the acceptance criteria and study details:

1. Table of Acceptance Criteria and Reported Device Performance (STTT comparison):

The document does not explicitly state pre-defined acceptance criteria for the comparative studies. Instead, it presents observed performance metrics (Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)) against a predicate device. For the purpose of this response, I will highlight the reported performance metrics from the comparative study.

1. Table of Acceptance Criteria and Reported Device Performance (MTTT Comparison):

Similar to the STTT comparison, the document reports observed performance metrics for the MTTT protocol against the STTT predicate.

2. Sample Size Used for the Test Set and Data Provenance:

For Comparison with Predicate Device (STTT):

• Sample Size: 520 serum samples.
• Data Provenance: Prospective samples submitted for Lyme serology testing. Collected from three sites (one internal and two external reference laboratories).

For MTTT Comparison (Prospective Study):

• Sample Size: 481 serum samples for the initial screening. Of these, 54 positive or equivocal samples were further tested.
• Data Provenance: Prospective samples submitted for Lyme serology testing. Collected from three sites (one internal and two external reference laboratories).

For Sensitivity Study (STTT and MTTT):

• Sample Size: 89 clinically characterized samples for STTT and 125 clinically characterized samples for MTTT.
• Data Provenance: Clinically characterized samples encompassing early, disseminated, and late stages of Lyme disease. The document doesn't specify geographical origin but implies a clinical context.

For CDC Panel (STTT and MTTT):

• Sample Size: 40 samples for STTT and 280 samples for MTTT.
• Data Provenance: Acquired from the Centers for Disease Control (CDC).

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications:

The document does not provide specific details on the number or qualifications of experts used to establish the ground truth for the test sets. The ground truth appears to be based on:

• "Clinically characterized samples" (for sensitivity studies).
• "Patients diagnosed with Lyme disease" and "healthy individuals" from the CDC panel.
• Comparison with predicate devices (for comparative studies).

4. Adjudication Method for the Test Set:

The document does not describe any specific adjudication method (e.g., 2+1, 3+1) for resolving discrepancies or establishing ground truth within the test sets. For comparative studies, the predicate device results largely serve as the reference, and for sensitivity studies, samples are clinically characterized, implying pre-existing diagnoses.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

This device is an in-vitro diagnostic (IVD) ELISA test kit, not an AI-powered image analysis or diagnostic tool that involves human readers. Therefore, an MRMC comparative effectiveness study involving human readers and AI assistance is not applicable and was not performed.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done:

The device is an ELISA test kit designed to provide a qualitative result (positive, equivocal, negative) based on optical density readings. It functions as a standalone diagnostic assay without a human-in-the-loop component in its primary function. The interpretation of the results by laboratory personnel is part of standard lab practice, but the "standalone performance" in this context refers to the assay's accuracy in detecting antibodies. The reported PPA, NPA, and sensitivity studies reflect this standalone performance.

7. The Type of Ground Truth Used (expert consensus, pathology, outcomes data, etc):

The ground truth used for different studies varies:

• Comparison Studies with Predicate Device: The results of the legally marketed predicate devices (Trinity Biotech Captia™ Borrelia burgdorferi IgG/IgM ELISA Test Kit and Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM Blot Tests) served as the reference standard.
• Sensitivity Studies: "Clinically characterized samples" and "patients diagnosed with Lyme disease" from the CDC panel. This implies a combination of clinical assessment, symptomology, and potentially other laboratory findings, which can be seen as a form of expert consensus or aggregated clinical data.
• Analytical Specificity and Cross-Reactivity: For analytical specificity, asymptomatic individuals from endemic and non-endemic regions were used. For cross-reactivity, samples confirmed positive for specific disease markers (from serum vendors) were used.

8. The Sample Size for the Training Set:

The document describes the determination of the assay cutoff but does not explicitly mention a "training set" in the context of machine learning or AI. For the cutoff determination:

• Assay Cutoff: 200 normal sera (100 from endemic, 100 from non-endemic regions).
• Verification: 125 characterized Lyme disease samples were used with the 200 normal samples for ROC analysis to verify the chosen cutoff.

9. How the Ground Truth for the Training Set Was Established:

As noted above, there isn't a "training set" in the typical AI sense. However, for the determination of the assay cutoff:

• Normal Sera: These were identified as "normal" based on their origin from non-diseased individuals in endemic and non-endemic regions.
• Characterized Lyme Disease Samples: These 125 samples were "characterized" for Lyme disease, implying a pre-established clinical diagnosis or a well-defined status as positive Lyme disease samples.

Ask a specific question about this device

The Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit is intended as a qualitative presumptive (first-step) test for the detection of IgG and IgM antibodies to B. burgdorferi sensu stricto in human serum from symptomatic patients or people suspected of infection. Positive and equivocal results must be supplemented by testing with a second-step Western blot assay.

The kit includes 12 x 8 well Antigen Coated strips, Conjugate, Substrate, Stop Solution, Wash Buffer. Diluent. Negative Control. Positive Control. The control. The controls are provided to determine if the assay is functioning properly and to determine the antibody level. The reagents are sufficient for 96 determinations.

During the test procedure, antibodies to B. burgdorferi (sensu stricto) if present in the human serum sample will bind to the antigens coated onto the wells forming antigen-antibody complexes. Excess antibodies are removed by washing. A conjugate of goat anti-human IgG/IgM antibodies conjugated with horseradish peroxidase are then added, which binds to the antigen-antibody complexes. Excess conjugate is removed by washing. This is followed by the addition of a chromogenic substrate, tetramethylbenzidine (TMB). If specific antibodies to the antigen are present in the patients' serum, a blue color will develop. The enzymatic reaction is then stopped with a stopping solution causing the contents of the well to turn yellow. The wells are read photometrically with a microplate reader at 450nm.

The antigens used in the Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test kit is a combination of B. burgdorferi sensu strain B31 lysate, B. burgdorferi sensu stricto strain 2591 lysate, and a recombinant VIsE from B. burgdorferi sensu stricto strain B31. The lysates use spirochetes growing in BSK-H complete medium until mid-exponential phase. The recombinant VlsE protein is produced in E. coli SURE2 cells and purified by affinity chromatography. The purity of each antigen is assayed by SDS-PAGE followed by Coomassie staining and/or Western blotting.

Here's an analysis of the acceptance criteria and the study proving the device meets them, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are not explicitly stated as distinct numerical targets in the provided document. Instead, the document demonstrates substantial equivalence to a predicate device and provides performance metrics from various studies. Based on the studies performed, the "reported device performance" is presented in the context of sensitivity, specificity, agreement with the predicate device, precision, and reproducibility.

2. Sample Sizes and Data Provenance

• Test Set (Clinical Studies):
  • Comparison with Predicate Device: 520 serum samples (prospective samples).
  • Sensitivity Study (Clinically Characterized): 89 clinically characterized samples.
  • CDC Panel: 40 samples (5 healthy, 35 Lyme disease stratified by stage).
  • Analytical Specificity: 210 asymptomatic individuals (110 from endemic region/Pennsylvania, 100 from non-endemic region/Arizona).
  • Cross-Reactivity: 221 samples (obtained from serum vendors, confirmed positive for respective markers).
  • Interfering Substances: 3 samples (negative, low positive, moderate positive, spiked).
  • Data Provenance: The data appears to be from a mix of regions within the US (Pennsylvania, Arizona for specificity, CDC for panel), and some samples from "serum vendors" for cross-reactivity. The clinical comparison study used "prospective samples submitted for Lyme serology testing" from three sites (one internal, two external reference laboratories). The sensitivity study used "clinically characterized samples."

3. Number of Experts and Qualifications for Ground Truth (Test Set)

• The document does not specify the number or qualifications of experts used to establish ground truth for the test set in the comparative clinical studies or sensitivity studies.
• For the "clinically characterized samples" and "patients diagnosed with Lyme disease" (CDC panel), it is implied that a clinical diagnosis (made by medical professionals) served as the ground truth, but no details on the specific experts (e.g., infectious disease specialists, their experience) are provided.
• For cross-reactivity, samples were from "serum vendors who confirmed their positivity for each respective marker," which likely relied on established diagnostic methods but doesn't detail expert involvement.

4. Adjudication Method (Test Set)

• The document does not describe a specific adjudication method (e.g., 2+1, 3+1, none) for resolving discrepancies in the test set.
• For the "Comparison with Predicate Device" table, "Equivocal samples counted as positive" is an interpretation rule, not an adjudication method for ground truth.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

• No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. This device is an in-vitro diagnostic (IVD) ELISA test kit, which is a laboratory assay and does not involve human readers interpreting results in the same way an imaging AI would. Therefore, the concept of human readers improving with AI assistance is not applicable here.

6. Standalone Performance (Algorithm Only)

• Yes, the performance presented for the "Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit" throughout the document (e.g., Precision, Reproducibility, Analytical Specificity, Cross-Reactivity, and its results in the Clinical Sensitivity and CDC Panel studies) is its standalone performance. This test kit is a self-contained diagnostic assay.

7. Type of Ground Truth Used

• Clinical Diagnosis/Characterization: For the sensitivity study and the CDC panel, the ground truth was based on "clinically characterized samples" and "patients diagnosed with Lyme disease," implying a clinical diagnosis by medical professionals.
• Absence of Disease/Asymptomatic Status: For the analytical specificity study, ground truth was derived from "asymptomatic individuals" from endemic and non-endemic regions, presumed to be negative for Lyme disease.
• Confirmed Positivity: For the cross-reactivity study, samples were from "serum vendors who confirmed their positivity for each respective marker."
• ELISA Results (Predicate Device): For the "Comparison with Predicate Device" study, the predicate device's results served as a comparative reference point, but not necessarily the ultimate gold standard for true disease status.

8. Sample Size for the Training Set

• The document implicitly references a "training set" for the establishment of the assay cutoff: "The cutoff was determined by testing a total of 200 normal sera which consisted of 100 sera from an endemic region of Lyme disease and 100 sera from a non-endemic region of Lyme disease."
• Additionally, after initial cutoff determination, "125 characterized Lyme disease samples were tested" and an ROC analysis was generated with the 325 samples (200 normal and 125 characterized samples) "to verify the chosen cutoff." This combined set of 325 samples served as a "training" or calibration set for optimizing the assay's cutoff.

9. How the Ground Truth for the Training Set was Established

• For the "training set" used to determine the assay cutoff:
  • Normal Sera: The 200 normal sera were obtained from "an endemic region of Lyme disease and a non-endemic region of Lyme disease." Their "normal" status implies they were considered negative for Lyme disease based on clinical assessment or lack of symptoms/exposure.
  • Characterized Lyme Disease Samples: The 125 "characterized Lyme disease samples" likely had a confirmed clinical diagnosis of Lyme disease, although specific details of this characterization are not provided. The phrase "characterized Lyme disease samples" implies a definitive diagnosis beyond just a positive test.

Ask a specific question about this device